Exerenibart for beta-thalassemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2024: Trial registered, NCT06421636
  2. 30 Sep 2024: Trial started, NCT06421636

The trials

NCT06421636: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

State
Under way
Phase
Phase 2
People
19 taking part
Started
30 Sep 2024
Primary completion
3 Dec 2026
Arms
Part A High Dose, Part A Low Dose, Part B High Dose, Part B Low Dose
Results
None posted
  1. 20 May 2024: Trial registered
  2. 30 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.